PMID- 22155063
OWN - NLM
STAT- MEDLINE
DCOM- 20120815
LR  - 20211021
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 38
IP  - 6
DP  - 2012 Oct
TI  - Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced 
      solid tumors: a meta-analysis.
PG  - 613-7
LID - 10.1016/j.ctrv.2011.10.008 [doi]
AB  - BACKGROUND: Paclitaxel is commonly given as a 3-h infusion every 3 weeks for a 
      variety of malignancies. Several randomized clinical trials comparing weekly 
      paclitaxel with Q3-week (Q3W) have produced mixed results in terms of efficacy 
      and toxicity creating controversy about the ideal dose and schedule. METHODS: A 
      literature search using PubMed, Cochrane Library, and Proceedings of the American 
      Society of Clinical oncology from 1995 to 2011 was performed. We included all 
      published and registered RTCs for advanced solid tumors which compared weekly 
      paclitaxel with Q3W. Primary dependent variables--grade 3, 4 neutropenia rates 
      and grade 3 sensory neuropathy rates--were analyzed for all cancer types. 
      Secondary dependent variables--hazard ratios for survival and response 
      rates--were analyzed for each cancer type. Moderators of cancer types, ethnicity, 
      and paclitaxel dose ratio were analyzed for primary dependent variables. RESULTS: 
      Ten trials were included. The summary effects of the meta-analysis revealed less 
      grade 3, 4 neutropenia (odds ratio: 0.49, p=0.0023) and a trend towards less 
      grade 3 sensory neuropathy (odds ratio: 0.54, p=0.092) with weekly paclitaxel 
      compared with Q3W. Moderator analysis by meta-regression revealed that paclitaxel 
      dose ratios have a significantly positive correlation with rates of G3/4 
      neutropenia and sensory neuropathy. In the five NSCLC (non small cell lung 
      cancer) trials, the summary effect revealed a better response rate with weekly 
      paclitaxel (odds ratio: 1.24, p=0.042). CONCLUSION: Weekly paclitaxel has a 
      favorable toxicity profile compared to the current standard of Q3W paclitaxel.
CI  - Copyright (c) 2011 Elsevier Ltd. All rights reserved.
FAU - Huang, Ta-Chen
AU  - Huang TC
AD  - University of Wisconsin Carbone Cancer Center, 600 Highland Avenue, Room 3051, 
      Madison, WI 53705-2275, USA. tchuang@medicine.wisc.edu
FAU - Campbell, Toby C
AU  - Campbell TC
LA  - eng
GR  - P30 CA014520/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20111210
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Antineoplastic Agents, Phytogenic/*administration & dosage/adverse effects
MH  - Humans
MH  - Neoplasm Staging
MH  - Neoplasms/*drug therapy/mortality/pathology
MH  - Paclitaxel/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2011/12/14 06:00
MHDA- 2012/08/16 06:00
CRDT- 2011/12/14 06:00
PHST- 2011/07/02 00:00 [received]
PHST- 2011/10/25 00:00 [revised]
PHST- 2011/10/31 00:00 [accepted]
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/08/16 06:00 [medline]
AID - S0305-7372(11)00236-2 [pii]
AID - 10.1016/j.ctrv.2011.10.008 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2012 Oct;38(6):613-7. doi: 10.1016/j.ctrv.2011.10.008. Epub 
      2011 Dec 10.